Realtimekurse aktiv
Tradegate
02.07.25 | 21:56
0,240 Euro
+0,46 % +0,001
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,238 | 0,239 | 02.07. | |
| 0,235 | 0,243 | 02.07. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | |
|---|---|---|---|---|
| 13.06. | Mersana Therapeutics, Inc. - 8-K, Current Report | 7 | SEC Filings | |
| 02.06. | Mersana reports promising Phase 1 ADC trial results | 17 | Investing.com | |
| MERSANA THERAPEUTICS Aktie jetzt für 0€ handeln | ||||
| 02.06. | Mersana Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | |
| 02.06. | Mersana Therapeutics, Inc.: Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting | 241 | GlobeNewswire (Europe) | |
| 27.05. | Mersana Therapeutics auf dem TD Cowen Summit: Strategische Updates zu Onkologie-Innovationen | 5 | Investing.com Deutsch | |
| 15.05. | Truist raises Mersana stock target to $10, maintains Buy rating | 29 | Investing.com | |
| 15.05. | Mersana Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | |
| 15.05. | Mersana Therapeutics GAAP EPS of -$0.19 in-line, revenue of $2.75M misses by $3.3M | 17 | Seeking Alpha | |
| 15.05. | Mersana Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | |
| 15.05. | Mersana Therapeutics, Inc.: Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results | 153 | GlobeNewswire (Europe) | |
| 06.05. | Bluebird pleads for deal support; Unity, Mersana lay off staff | 10 | BioPharma Dive | |
| 06.05. | Mersana makes Emi-Le the one, laying off 55% of staff to narrow focus to B7-H4 ADC | 3 | FierceBiotech | |
| 06.05. | Mersana Therapeutics kündigt strategische Kürzungen | 6 | Investing.com Deutsch | |
| 06.05. | Mersana Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | |
| 06.05. | Mersana Therapeutics, Inc.: Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer | 137 | GlobeNewswire (Europe) | |
| 23.04. | Mersana Therapeutics, Inc.: Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting | 9 | GlobeNewswire (USA) | |
| 04.04. | Mersana Therapeutics, Inc.: Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 353 | GlobeNewswire (Europe) | |
| 01.04. | Mersana Therapeutics, Inc.: Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress | 12 | GlobeNewswire (USA) | |
| 04.03. | Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2024 Earnings Call Transcript | 21 | Insider Monkey | |
| 03.03. | Mersana Therapeutics, Inc. - 10-K, Annual Report | 2 | SEC Filings |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
MERSANA THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,240 Euro und damit +0,46 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MERSANA THERAPEUTICS INC finden Sie auf Wallstreet Online.